


Bulevirtide: a success case after PegINFα failure

A. Carraro¹, R. Marocco¹, B. Kertusha¹, G. Mancarella¹, L. Ansaldo¹, L. Fondaco¹, S. De Maria¹, S. Corazza¹, A. Gasperin¹, A. Grimaldi¹, C. Del Borgo¹, M. Lichtner²
¹Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome Polo Pontino, Latina, Italy ²Department of NESMOS, Sapienza University of Rome, Rome, Italy


Introduction

- Bulevirtide: a therapy under study
 - How long the treatment?
 - In combination with others therapy?
- It is important to collect as much data as possible on bulevirtide treatment to observe its efficacy and its limits in real life.

Case report

- 
- nationality: Albanian
 - age: 34 years old
 - gender: male
 - With a HBV – HDV coinfection diagnosis since 2019


At the diagnosis:

- 
- Elastography: stiffness of 8.8 Kpa (METAVIR F3),
 - HBV DNA 9830 UI/ml, HBsAg 23996 UI/ml,
 - HDV RNA 29475 copies/ml,
 - GOT 45 U/I, GPT 92U/I.

After 4 months:

- 
- Tenofovir disoproxil 245mg/die treatment was started

After 7 months:

- 
- PegINF α 180 mcg/week treatment was started




After 20 treatment weeks :

- HBV DNA 15 copies/ml
- HDV RNA 111000 copies/ml
- GOT 84U/I and GPT 199U/I.

After 48 treatment weeks (the end):


- HDV RNA 435 copies/ml

Side effect:

- 
- Arthralgias
 - An episode of fever

Follow up after PegINFα

- HDV RNA increasing, confirmed at several times
- March 2023: HDV 51060 copies/ml
- July 2023: HDV 391890 copies/ml



Peg INFα was not durable

Bulevirtide: a new chance




November 2023:

- Bulevirtide 2mg/sc/day treatment was started




- He did not complain of any systemic disorders or local skin and subcutaneous reactions.



- After 2 months: HDV viremia has decreased and transaminases have normalized
- After 8 months: transaminases are within normal values and HDV viremia is undetectable with the current method.

	11/07/19	01/12/19	01/07/20	01/03/23	01/07/23	12/10/23	14/12/23	12/01/24	08/02/24	29/03/24	08/05/24	12/07/24
GOT (U/I)	45	84	90	60	50	45	38	32	32	34	30	32
GPT (U/I)	92	199	100	79	80	86	61	39	35	34	33	33
Biliary acids (micromols/l)							52	119	11	82	33	58
HDV RNA (cp/ml)	29475	111000	435	51060	391890	13170	10650		180		<100	



Conclusion

- Bulevirtide is effective to reduce HDV viral replication
- Bulevirtide is effective to reduce liver damage following PegINF α failure
- Bulevirtide is also well tolerated.

Reference

1. Current and future management of Chronic Hepatitis D, Farci P, Niro G et al. 2018
2. An uptodate to management of chronic hepatitis D, Shah P, Choudhry S et al. 2019
3. EASL Practice guidelines on hepatitis delta virus, 2023